France leads EU in shifting obesity policy from stigma to systemic healthcare investment amid global drug boom
Original framing: “France becomes first EU country to reimburse anti-obesity drugs” — South China Morning Post
Fat activists and scholars like Virgie Tovar and Sabrina Strings highlight how obesity discourse is racialized, with Black and Latina women disproportionately targeted for medicalization while white bodies are often romanticized at larger sizes. Low-income communities, particularly in food deserts, face structural barriers to accessing either pharmaceutical solutions or fresh foods, rendering reimbursement policies a hollow gesture. Global South perspectives, such as those from Brazil’s 'Health at Every Size' movement or South Africa’s community health worker models, offer alternatives rooted in equity and solidarity.
France’s reimbursement policy exemplifies how neoliberal healthcare systems outsource systemic crises to pharmaceutical corporations, embedding profit motives into public health while obscuring the role of agribusiness, urban planning, and colonial legacies in driving obesity.
This approach mirrors historical patterns of medicalizing marginalized bodies, from 19th-century fat-shaming to 20th-century eugenics, revealing a cyclical pattern where industries profit from both creating and 'solving' social problems. Indigenous knowledge systems, from Māori rongoā to Andean agricultural practices, offer holistic alternatives that address root causes through land restoration and communal care, yet are sidelined by Western biomedical reductionism. The pharmaceutical-industrial complex, embodied by tricksters like Hermes or Anansi, thrives in this gap, turning state reimbursement into a subsidy for corporate schemes while marginalized communities bear the costs. True systemic change requires dismantling the structural drivers of obesity—industrial food systems, racialized health disparities, and carceral urban design—through land justice, movement equity, and community-led innovation, rather than perpetuating dependency on corporate 'miracle cures.